If you need a PDF, please email Eachan.

While at the Francis Crick Institute (2021–)

Evolution of Mycobacterium tuberculosis drug resistance in the genomic era
Nimmo C, Millard J, Faulkner V, Monteserin J, Pugh H , Johnson EO
Frontiers in Cellular and Infection Microbiology, Oct 2022, 12: 954074 | PubMed ID: 36275027

While at the Broad Institute (2014-2020)

Using Proteolytic Hypomorphs to Detect Small Molecule Mechanism of Action
Johnson EO, Hung DT
Methods in Molecular Biology,
Jun 2021, 2314, 323–342 | PubMed ID: 34235661

Large-scale chemical-genetic strategy to design antimicrobial combination chemotherapy for Mycobacterium tuberculosis
Johnson EO, Office E, Kawate T, Orzechowski M, Hung DT
ACS Infectious Diseases, Jan 2020, 6(1), 56–63 | PubMed ID: 31721551 

A point of inflection and reflection on systems chemical biology
Johnson EO, Hung DT
ACS Chemical Biology, Dec 2019, 14(12), 2497–2511 | PubMed ID: 3161359

Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes
Johnson EO, LaVerriere E, Office E, Stanley M, Meyer E, Kawate T, Gomez J, Audette RE, Bandyopadhyay N, Betancourt N, Delano K, Da Silva I, Davis J, Gallo C, Gardner M, Golas A, Guinn KM, Kennedy S, Korn R, McConnell JA, Moss CE, Murphy KC, Nietupski R, Papavinasasundaram KG, Pinkham JT, Pino PA, Proulx MK, Ruecker N, Song N, Thompson M, Trujillo C, Wakabayashi S, Wallach JB, Watson C, Ioerger TR, Lander ES, Hubbard BK, Serrano-Wu MH, Ehrt S, Fitzgerald M, Rubin EJ, Sassetti CM, Schnappinger D, Hung DT
Nature, Jul 2019, 571, 72-78 | PubMed ID: 31217586 

While at University of Oxford (2009-2013)

A structural model of a P450-ferredoxin complex from orientation-selective double electron-electron resonance spectroscopy

Bowen AM, Johnson EO, Mercuri F, Hoskins NJ, Qiao R, McCullagh JSO, Lovett JE, Bell SG, Zhou W, Timmel CR, Wong LL, Harmer JR

Journal of the American Chemical Society, Feb 2018, 140(7), 2514-2527 | PubMed ID: 29266939

Partial fusion of a cytochrome P450 system by carboxy-terminal attachment of putidaredoxin reductase to P450cam (CYP101A1)

Johnson EO, Wong LL

Catalysis Science and Technology, Sep 2016, 6(20), 7549-7560 | PubMed ID: 28944003

Tailoring an alien ferredoxin to support native-like P450 monooxygenase activity

Bell SG, McMillan JH, Yorke JA, Kavanagh E, Johnson EO, Wong LL

Chemical Communications, Dec 2012, 48(95), 11692-11694 | PubMed ID: 23104016

Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation

Boehringer J, Riedinger C, Paraskevopoulos K, Johnson EO, Lowe ED, Khoudian C, Smith D, Noble ME, Gordon C, Endicott JA

Biochemical Journal, Nov 2012, 448(1), 55-65 | PubMed ID: 22906049

The crystal structures of 4-methoxybenzoate bound CYP199A2 and CYP199A4: structural changes on substrate binding and the identification of an anion binding site

Bell SG, Yang W, Tan AB, Zhou R, Johnson EO, Zhang A, Zhou W, Rao Z, Wong LL

Dalton Transactions, Jul 2012, 41(28), 8703-8714 | PubMed ID: 22695988

Selective oxidative demethylation of veratric acid to vanillic acid by CYP199A4 from Rhodopseudomonas palustris HaA2

Bell SG, Tan AB, Johnson EO, Wong LL

Molecular BioSystems, Jan 2010, 6(1), 206-214 | PubMed ID: 20024082

Protein recognition in ferredoxin-P450 electron transfer in the class I CYP199A2 system from Rhodopseudomonas palustris

Bell SG, Xu F, Johnson EO, Forward IM, Bartlam M, Rao Z, Wong LL

Journal of Biological Inorganic Chemistry, Mar 2010, 15(3), 315-28 | PubMed ID: 19904564

Crystal structure of a ferredoxin reductase for the CYP199A2 system from Rhodopseudomonas palustris

Xu F, Bell SG, Peng Y, Johnson EO, Bartlam M, Rao Z, Wong LL

Proteins, Dec 2009, 77(4), 867-880 | PubMed ID: 19626710